Godrej Agrovet Limited (GODREJAGRO) Q1 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

Godrej Agrovet enters Q1 FY27 results facing a complex operating environment defined by volatile commodity prices and a delayed monsoon impacting its agricultural segments. Investors will be closely watching for signs of margin resilience in the Animal Nutrition and Dairy businesses alongside the sustainability of the turnaround at Astec LifeSciences.

Godrej Agrovet Limited Q1 Results Date and Time

The board meeting is scheduled for August 5, 2026, to consider and approve the unaudited standalone and consolidated financial results for Q1 FY27.

The earnings conference call is scheduled for August 6, 2026, at 3:30 PM IST, hosted by Anand Rathi Research.

What to expect from Godrej Agrovet Limited's Q1 FY27 results

Management has set a base-case expectation of early double-digit consolidated revenue growth and mid-teens PBT growth for FY27, though leadership has indicated these are preliminary targets currently under review. The Oil Palm segment, which contributed 40% of PBIT in FY26, faces a headwind from lower CPO realizations compared to the Rs. 1,14,079/MT seen in Q1 FY26, though volume growth remains a key offsetting lever. Animal Nutrition and Dairy segments are navigating significant input cost pressures, with soyameal prices surging approximately 40% recently and milk procurement inflation reaching 10% in Maharashtra. Crop Protection is expected to remain weak in Q1 due to a 23% YoY slump in kharif sowing, with management positioning the segment for a recovery starting in Q2. The upcoming call will focus on the sustainability of the Astec LifeSciences turnaround following its FY26 EBITDA break-even and the impact of recent raw material inflation on consolidated margins.

Key Things To Watch

Performance vs Guidance Tracking: Monitoring progress against management's stated FY27 targets.

• Consolidated revenue growth — early double-digit target — tracking vs Q1 baseline
• Mid-teens PBT growth — target for FY27 — margin trajectory vs revenue
• Oil Palm — beat FY26 record area expansion — progress on FY27 expansion targets
• Astec — ~15% revenue growth — Q1 growth rate and CDMO vs Enterprise mix

Palm Oil Price Volatility: Assessing the impact of geopolitical and market factors on Oil Palm realizations.

• CPO and PKO realizations in Q1 FY27 vs Q1 FY26 (Rs. 1,14,079/MT) and Q4 FY26 (Rs. 1,20,422/MT)
• Impact of Iran war and shipping costs on segment margins
• Updated guidance on FY27 palm oil outlook

Astec LifeSciences Turnaround: Evaluating if the FY26 EBITDA break-even is sustainable.

• Q1 FY26 revenue was Rs. 91 Cr with negative EBITDA of Rs. 11 Cr
• CDMO margin performance vs Enterprise business
• Sustainability of turnaround into the seasonally weaker Q1

Dairy Margin Inflection: Tracking the impact of procurement inflation and price hikes.

• Milk procurement inflation trend in Maharashtra vs 10% level in FY26
• VAP salience improvement from 40% in Q4 FY26
• EBITDA margin recovery path following H1 FY26 level of 4.5%

Crop Care Recovery: Monitoring the impact of weather and new product launches.

• Q1 performance in context of delayed monsoon and 23% slump in kharif sowing
• Traction of new product Ashitaka launched in July 2025
• Status of inventory carry-forward impacts from FY26